Rabbit anti-Human CD55 Monoclonal Antibody for Flow Cytometry - P08174

Core Product Specifications and Parameters

Biological Background: CD55 (Complement Decay-Accelerating Factor) Function and Localization

• CD55, also known as decay-accelerating factor (DAF), is a glycophosphatidylinositol (GPI)-anchored membrane protein that belongs to the regulators of complement activation (RCA) family.
• It recognizes C4b and C3b fragments deposited on cell surfaces and interferes with their ability to catalyze the conversion of C2 and factor B, thereby preventing the formation of the C4b2a and C3bBb amplification convertases. Related references: PMID:7525274
• By destabilizing and inhibiting the assembly of C3 and C5 convertases, CD55 protects autologous cells from complement-mediated lysis and tissue damage. Related references: PMID:28657829
• Beyond complement regulation, CD55 serves as a cellular receptor for diverse picornaviruses, including coxsackievirus A21, coxsackieviruses B1, B3, B5, human enterovirus 70 and D68, and echoviruses 6, 7, 11, 12, 20, and 21.
• It is expressed on the plasma membrane of virtually all cells that contact plasma complement proteins, as well as on epithelial cells lining extracellular compartments; soluble forms are also found in body fluids and the extracellular matrix.
• The protein contains multiple N-linked glycosylation sites and four N-terminal sushi (CCP) domains, which are essential for ligand binding; alternative splicing generates GPI-anchored and secreted variants.
• Clinically, mutations in CD55 are linked to CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy), and the molecule carries the Cromer blood group antigens.
• The mature polypeptide has a predicted mass of ~41 kDa, but extensive glycosylation results in a heterogeneous band pattern ranging from 39 kDa to 59 kDa in western blotting.

Experimental Guidance and Technical Tips

• The immunogen covers the entire extracellular domain (aa 35–353), suggesting that the antibody binds native CD55 on live cells; validate staining under non-permeabilizing conditions for surface detection.
• For flow cytometry, titrate the antibody across a 0.1–5 µg/mL range using human peripheral blood mononuclear cells or CD55-transfected cell lines to determine the optimal concentration.
• Include appropriate isotype controls and Fc receptor blocking reagents to minimize non‑specific binding, especially in samples with high FcγR expression.
• Because CD55 is shed from the membrane, consider staining both primary cells and matched supernatants if investigating soluble forms.
• Verify cross‑reactivity in your specific experimental system; the antibody is reported to react with human CD55, but performance in non‑human primates or rodent models should be confirmed individually.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, contract research organizations, and academic labs with end‑to‑end access to high‑quality IVD raw materials, technical services, and strategic consulting. This anti‑CD55 monoclonal antibody, validated for flow cytometry, supports complement cascade research and viral entry studies—CamelBio can further supply validated antibody pairs, bulk ancillary reagents, and customized rare‑target sourcing to accelerate your assay development from concept to clinical application.